FDA Accepts Supplemental BLA and Grants Priority Review for ADCETRIS...

FDA Accepts Supplemental BLA and Grants Priority Review for ADCETRIS in the AETHERA Setting for the Post-Transplant Consolidation Treatment of Hodgkin Lymphoma Patients at High Risk of Relapse Seattle Genetics, Inc. announced today that the U.S. Food and Drug Administration has accepted for filing a supplemental Biologics License Application for ADCETRIS in the AETHERA setting for the post-transplant consolidation treatment of Hodgkin lymphoma patients at high risk of relapse or progression. The FDA granted Priority Review for the application and the Prescription Drug User Fee Act target action date is August 18, 2015.
http://ift.tt/1E2OZD9